Skip to main content
SpringerLink
Log in

Usability of FDA-Approved Medication Guides

Journal of General Internal Medicine volume 27, pages 1714–1720 (2012)Cite this article

Abstract

BACKGROUND

Medication guides are required documents to be distributed to patients in order to convey serious risks associated with certain prescribed medicines. Little is known about the effectiveness of this information to adequately inform patients on safe use.

OBJECTIVE

To examine the readability, suitability, and comprehensibility of medication guides, particularly for those with limited literacy.

DESIGN

Assessments of suitability and readability of 185 medication guides, and a sub-study examining change in suitability and readability from 2006 to 2010 among 32 of the medication guides (Study 1); ‘open book’ comprehension assessment of medication guides (Study 2).

SETTING

Two general internal medicine clinics in Chicago, IL.

PATIENTS

Four hundred and forty-nine adults seeking primary care services, ages 18–85.

MEASUREMENTS

For Study 1, the Suitability Assessment of Materials (SAM) and Lexile score for readability. For Study 2, a tailored comprehension assessment of content found in three representative medication guides.

RESULTS

The 185 analyzed medication guides were on average 1923 words (SD = 1022), with a mean reading level of 10–11th grade. Only one medication guide was deemed suitable in SAM analyses. None provided summaries or reviews, or framed the context first, while very few were rated as having made the purpose evident (8 %), or limited the scope of content (22 %). For Study 2, participants’ comprehension of medication guides was poor (M = 52.7 % correct responses, SD = 22.6). In multivariable analysis, low and marginal literacy were independently associated with poorer understanding (β = –14.3, 95 % CI –18.0 – –10.6, p < 0.001; low: β = –23.7, 95 % CI –28.3 – –19.0, p < 0.001).

CONCLUSION

Current medication guides are of little value to patients, as they are too complex and difficult to understand especially for individuals with limited literacy. Explicit guidance is offered for improving these print materials.

This is a preview of subscription content, access via your institution.

Access options

Buy single article

Instant access to the full article PDF.

USD 39.95

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Figure 1.

References

  1. Department of Health and Human Services. Prescription Drug Product Labeling: medication guide Requirements; Final Rule. Fed Regist. 1998;63:66378–400.

    Google Scholar 

  2. Department of Health and Human Services. medication guides for Prescription Drug Products. Title 21 Code of Federal Regulations. Pt. 208. 2004:115-6.

  3. U.S. Food and Drug Administration. Guidance for Industry: Format and Content of Proposed Risk Evaluation and Mitigation Strategies (REMS), REMS Assessments and Proposed REMS Modifications. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM184128.pdf. Accessed March 29, 2012

  4. U.S. Food and Drug Administration, Center for Drug Evaluation Research (CDER). Guidance for Industry: medication guides - Distribution Requirements and Inclusion in Risk Evaluation and Mitigation Strategies (REMS). http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM244570.pdf. Accessed March 29, 2012.

  5. Stubbings J, Joshi RA, Hoffman JM. Risk evaluation and mitigation strategies: challenges and opportunities for health-system pharmacists. Am J Health Syst Pharm. 2010;67:1547–54.

    Article  PubMed  Google Scholar 

  6. Hennessy KF, Williams KG, Bongero D. Safer use of medications through risk evaluation and mitigation strategies: Academy perspectives. J Am Pharm Assoc (2003). 2010;50:556-62.

    Google Scholar 

  7. Morris LA, Tabak ER, Gondek K. Counseling patients about prescribed medication: 12-year trends. Med Care. 1997;35:996–1007.

    Article  PubMed  CAS  Google Scholar 

  8. Metlay JP, Cohen A, Polsky D, Kimmel SE, Koppel R, Hennessy S. Medication safety in older adults: home-based practice patterns. J Am Geriatr Soc. 2005;53:976–82.

    Article  PubMed  Google Scholar 

  9. Sleath B, Roter D, Chewning B, Svarstad B. Asking questions about medication: analysis of physician-patient interactions and physician perceptions. Med Care. 1999;37:1169–73.

    Article  PubMed  CAS  Google Scholar 

  10. Stevenson FA, Cox K, Britten N, Dundar Y. A systematic review of the research on communication between patients and health care professionals about medicines: the consequences for concordance. Health Expect. 2004;7:235–45.

    Article  PubMed  Google Scholar 

  11. Allen LaPointe NM, Pappas P, Deverka P, Anstrom KJ. Patient receipt and understanding of written information provided with isotretinoin and estrogen prescriptions. J Gen Intern Med. 2007;22:98-101.

    Google Scholar 

  12. Wolf MS, Davis TC, Shrank WH, Neuberger M, Parker RM. A critical review of FDA-approved medication guides. Patient Educ Couns. 2006;62:316–22.

    Article  PubMed  Google Scholar 

  13. Wallace LS, Roskos S, Weiss BD. Readability characteristics of consumer medication information for asthma inhalation devices. J Asthma. 2006;43:375–8.

    Article  PubMed  Google Scholar 

  14. The Keystone National Policy Dialogue on Food. Nutrition, and Health: The Final Report. Keystone: The Keystone Center; 1996.

    Google Scholar 

  15. Shrank WH, Agnew-Blais J, Choudhry NK, et al. The variability and quality of medication container labels. Arch Intern Med. 2007;167:1760–5.

    Article  PubMed  Google Scholar 

  16. U.S. Food and Drug Administration. Public Hearing on Use of medication guides to Distribute Drug Risk Information. Washington, DC; June 12-13, 2007.

  17. U.S. Food and Drug Administration. Providing Effective Information to Consumers About Prescription Drug Risks and Benefits. Public Workshop. Gaithersburg, MD; September 24-25, 2009.

  18. Department of Health and Human Services. Experimental Study of Patient Information Prototypes. Fed Regist. 2010;75:78252–6.

    Google Scholar 

  19. Brookings Institution. The Science of Communicating Medication Information to Consumers. An Engelberg Center for Healthcare Reform Event. Washington DC; July 21, 2010.

  20. Doak CC, Doak LG, Root JH. Assessing Suitability of Materials. Teaching Patients with Low Literacy Skills. 2nd ed. Philadelphia: JB Lippincott; 1996.

  21. Lennon C, Burdick H. The Lexile Framework as an Approach for Reading Measurement and Success. Durham: MetaMetrics, Inc.; 2004.

    Google Scholar 

  22. Wolf MS, Shekelle P, Choudhry NK, Agnew-Blais J, Parker RM, Shrank WH. Variability in pharmacy interpretations of physician prescriptions. Med Care. 2009;47:370–3.

    Article  PubMed  Google Scholar 

  23. Callahan CM, Unverzagt FW, Hui SL, Perkins AJ, Hendrie HC. Six-item screener to identify cognitive impairment among potential subjects for clinical research. Med Care. 2002;40:771–81.

    Article  PubMed  Google Scholar 

  24. Davis TC, Long SW, Jackson RH, et al. Rapid estimate of adult literacy in medicine: a shortened screening instrument. Fam Med. 1993;25:391.

    PubMed  CAS  Google Scholar 

  25. U.S. Food and Drug Administration, Center for Drug Evaluation Research (CDER). medication guides. http://www.fda.gov/drugs/drugsafety/UCM085729.htm. Accessed March 29, 2012.

  26. Rosenthal MB, Berndt ER, Donohue JM, Frank RG, Epstein AM. Promotion of prescription drugs to consumers. Vol. 2002;346:498–505.

    Google Scholar 

  27. Krass I, Svarstad BL, Bultman D. Using alternative methodologies for evaluating patient medication leaflets. Patient Educ Couns. 2002;47:29–35.

    Article  PubMed  Google Scholar 

  28. Gustafsson J, Kälvemark S, Nilsson G, Nilsson JLG. Patient information leaflets—patients’ comprehension of information about interactions and contraindications. Pharm World Sci. 2005;27:35–40.

    Article  PubMed  Google Scholar 

  29. Plain Language Action and Information Network (PLAIN). Improving Communcation from the Federal Government to the Public. Plain Language: It's the law http://www.plainlanguage.gov/plLaw/index.cfm. Accessed March 29, 2012.

  30. National Work Group on Literacy and Health. Communicating with patients who have limited literacy skills: Report of the National Work Group on Literacy and Health. J Fam Pract. 1998;46:168–76.

    Google Scholar 

  31. Agency for Healthcare Research and Quality (AHRQ). Contract HHSA2902009000121: Educational tools and resources to support meaningful use of electronic health records (Abt Associates).

  32. Institute of Medicine. Health literacy: A prescription to end confusion. Washington DC: National Academy Press; 2004.

    Google Scholar 

  33. Wolf MS, Davis TC, Tilson HH, Bass PF 3rd, Parker RM. Misunderstanding of prescription drug warning labels among patients with low literacy. Am J Health Syst Pharm. 2006;63:1048–55.

    Article  PubMed  Google Scholar 

  34. Davis TC, Wolf MS, Bass PF 3rd, et al. Low literacy impairs comprehension of prescription drug warning labels. J Gen Intern Med. 2006;21:847–51.

    Article  PubMed  Google Scholar 

  35. Davis TC, Wolf MS, Bass PF 3rd, et al. Literacy and misunderstanding prescription drug labels. Ann Intern Med. 2006;145:887–94.

    PubMed  Google Scholar 

  36. Wilson E, Chen AH, Grumbach K, Wang F, Fernandez A. Effects of limited English proficiency and physician language on health care comprehension. J. Gen. Intern. Med. 2005;20(9):800–6.

    Article  PubMed  Google Scholar 

  37. Sharif I, Tse J. Accuracy of Computer-Generated, Spanish-Language Medicine Labels. Pediatrics 2010;125(5):960–965.

  38. Leyva M, Sharif I, Ozuah PO. Health literacy among Spanish-speaking Latino parents with limited English proficiency. Ambul Pediatr. 2005;5(1):56–9.

    Article  PubMed  Google Scholar 

Download references

Acknowledgments

This project was supported by an unrestricted grant from Abbott Labs (PI: Wolf).

Conflict of Interest

Drs. Wolf and Bailey have served as paid consultants to Abbott Labs for research services and advisory committee activities. Both Drs. Davis and Wolf have served as paid consultants to McNeil Consumer Healthcare in service for advisory board membership on drug labeling initiatives.

Competing Interests

Drs. Wolf, Davis, and Lambert have previously provided research consultation services to Abbott Labs.

Author information

Authors and Affiliations

  1. Health Literacy and Learning Program, Division of General Internal Medicine, Feinberg School of Medicine at Northwestern University, 750 N. Lake Shore Drive, 10th Floor, Chicago, IL, 60611, USA

    Michael S. Wolf PhD, MPH, Jennifer King MPH, Elizabeth A. H. Wilson PhD, Laura M. Curtis MS, Stacy Cooper Bailey PhD, MPH, Allison Russell BA, Ashley Bergeron MPH & Amanda Daly BA

  2. Department of Learning Sciences, School of Education and Social Policy, Northwestern University, Evanston, IL, USA

    Michael S. Wolf PhD, MPH

  3. Department of Pharmacy Administration, University of Illinois at Chicago College of Pharmacy, Chicago, IL, USA

    James Duhig PhD & Bruce Lambert PhD

  4. Division of General Medicine, Emory University School of Medicine, Atlanta, GA, USA

    Ruth M. Parker MD

  5. Department of Medicine-Pediatrics, Louisiana State University Health Sciences Center, Shreveport, LA, USA

    Terry C. Davis PhD

  6. Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, USA

    William H. Shrank MD, MSHS

Authors
  1. Michael S. Wolf PhD, MPH
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jennifer King MPH
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Elizabeth A. H. Wilson PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Laura M. Curtis MS
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Stacy Cooper Bailey PhD, MPH
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. James Duhig PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Allison Russell BA
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Ashley Bergeron MPH
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Amanda Daly BA
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Ruth M. Parker MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Terry C. Davis PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. William H. Shrank MD, MSHS
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Bruce Lambert PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Michael S. Wolf PhD, MPH.

Electronic supplementary material

Below is the link to the electronic supplementary material.

ESM 1

(DOC 47 kb)

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Wolf, M.S., King, J., Wilson, E.A.H. et al. Usability of FDA-Approved Medication Guides. J GEN INTERN MED 27, 1714–1720 (2012). https://doi.org/10.1007/s11606-012-2068-7

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11606-012-2068-7

KEY WORDS

search

Navigation